# TREM2 Receptor Modulation Synthesis Analysis
```json
{
"ranked_hypotheses": [
{
"rank": 1,
"hypothesis_id": "H3",
"hypothesis_name": "SYK Inhibition Downstream of TREM2",
"target": "SYK",
"composite_score": 0.63,
"scores": {
"mechanistic_plausibility": 0.82,
"evidence_strength": 0.75,
"novelty": 0.35,
"feasibility": 0.78,
"therapeutic_potential": 0.68,
"druggability": 0.82,
"safety_profile": 0.58,
"competitive_landscape": 0.52,
"data_availability": 0.72,
"reproducibility": 0.68
},
"evidence_for": [
{
"claim": "SYK is the obligate downstream kinase for TREM2-TYROBP signaling",
"pmid": "28935867"
},
{
"claim": "Fostamatinib (SYK inhibitor) is FDA-approved for ITP with acceptable safety profiles",
"pmid": "29053630"
},
{
"claim": "SYK has shorter signaling half-life than receptor activation, enabling rapid on/off control",
"pmid": "30048316"
},
{
"claim": "SYK inhibitors cross blood-brain barrier (clinical data in neurological indications)",
"pmid": "29053630"
}
],
"evidence_against": [
{
"claim": "SYK inhibitors have off-target toxicity due to broad SYK expression across immune cell types",
"pmid": "29053630"
},
{
"claim": "Complete SYK inhibition may impair beneficial microglial surveillance functions",
"pmid": "28935867"
}
],
"synthesis_notes": "Strongest practical hypothesis. Fostamatinib already approved; enables therapeutic tuning of microglial activation without direct receptor manipulation. Key challenge: achieving CNS-penetrant selectivity for microglial SYK while sparing peripheral immune function.",
"confidence_practical_translation": 0.72
},
{
"rank": 2,
"hypothesis_id": "H5",
"hypothesis_name": "PLCγ2 Selective Activation Bypass",
"target": "PLCG2",
"composite_score": 0.50,
"scores": {
"mechanistic_plausibility": 0.62,
"evidence_strength": 0.55,
"novelty": 0.72,
"feasibility": 0.38,
"therapeutic_potential": 0.65,
"druggability": 0.28,
"safety_profile": 0.42,
"competitive_landscape": 0.55,
"data_availability": 0.48,
"reproducibility": 0.58
},
"evidence_for": [
{
"claim": "PLCγ2 is the obligate downstream effector of TREM2/TYROBP",
"pmid": "29229958"
},
{
"claim": "PLCγ2 activating mutations cause constitutive activation without receptor input",
"pmid": "29229958"
},
{
"claim": "PLCγ2 SH2 domain structures enable allosteric activator design",
"pmid": "29229958"
}
],
"evidence_against": [
{
"claim": "No direct PLCγ2 activators exist in literature or clinical pipelines",
"pmid": "29229958"
},
{
"claim": "Enzyme activation carries higher safety risk than inhibition (uncontrolled signaling)",
"pmid": "292